Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow

Satoru Morikawa,1,2 Yo Mabuchi,1 Yoshiaki Kubota,3 Yasuo Nagai,1 Kunimichi Niibe,1,2 Emi Hiratsu,1 Sadafumi Suzuki,1 Chikako Miyauchi-Hara,1,6 Narihito Nagoshi,1,4 Takehiko Sunabori,1 Shigeto Shimmura,5 Atsushi Miyawaki,6,7 Taneaki Nakagawa,2 Toshio Suda,3 Hideyuki Okano,1 and Yumi Matsuzaki1

1Department of Physiology, 2Department of Dentistry and Oral Surgery, 3Department of Cell Differentiation, the Sakaguchi Laboratory of Developmental Biology, 4Department of Orthopedic Surgery and 5Department of Ophthalmology, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan
6Laboratory for Cell Function and Dynamics, Advanced Technology Development Group, Brain Science Institute, Institute of Physical and Chemical Research, Wako-city, Saitama 351-0198, Japan
7Life Function and Dynamics, Exploratory Research for Advanced Technology Office, Japan Science and Technology Agency, Wako-city, Saitama 351-0198, Japan

Mesenchymal stem cells (MSCs) are defined as cells that undergo sustained in vitro growth and can give rise to multiple mesenchymal lineages. Because MSCs have only been isolated from tissue in culture, the equivalent cells have not been identified in vivo and little is known about their physiological roles or even their exact tissue location. In this study, we used phenotypic, morphological, and functional criteria to identify and prospectively isolate a subset of MSCs (PDGFRα+Sca-1+CD45−TER119−) from adult mouse bone marrow. Individual MSCs generated colonies at a high frequency and could differentiate into hematopoietic niche cells, osteoblasts, and adipocytes after in vivo transplantation. Naive MSCs resided in the perivascular region in a quiescent state. This study provides the useful method needed to identify MSCs as defined in vivo entities.

Adult BM is composed of hematopoietic stem cells (HSCs) and tissue stem cells, which are often referred to as fibroblast CFUs (CFU-Fs), narrow stromal cells/mesenchymal stem cell; HSC, hematopoietic stem cell; IHCl, immunohistochemistry; mMSC, murine MSC; MPC, mesenchymal progenitor cell; MSC, mesenchymal stem cell; PDGFRα, platelet-derived growth factor receptor α; Sca-1, stem cell antigen 1; vSMC, vascular smooth muscle cell.

Abbreviations used: BLI, bioluminescence imaging; BM-MNC, BM mononuclear cell; CFU-F, fibroblast CFU; CFU-S, spleen CFU; HSC, hematopoietic stem cell; IHC, immunohistochemistry; mMSC, murine MSC; MPC, mesenchymal progenitor cell; MSC, mesenchymal stem cell; PDGFRα, platelet-derived growth factor receptor α; Sca-1, stem cell antigen 1; vSMC, vascular smooth muscle cell.

© 2009 Morikawa et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
Figure 1. Enrichment of mesenchymal stem cells in the PaS population. (A–D) Representative flow cytometric profiles of BM mononuclear cells stained with CD45, TER119, PDGFRα, and Sca-1 without (A and B) or with (C and D) collagenase treatment. (E) Number of CFU-Fs 14 d after plating. Data
progress in understanding their biology. In contrast, because our knowledge of MSCs is based solely on the characterization of cultured cells, it has been virtually impossible to study many of their properties, particularly their function, in vivo.

Recent studies consistently show that MSCs not only differentiate into mesenchymal lineage cells but also into neurons (Kohyama et al., 2001; Konado et al., 2005), skeletal muscle (Dezawa et al., 2005), and myocardium (Makino et al., 1999; Miyahara et al., 2006). Therefore, MSCs are now considered a potentially effective source for stem cell therapy (Jin et al., 2002; Hoffmann et al., 2006). However, safety issues still need to be clarified before their clinical use, particularly because so many biological aspects of MSCs, such as their exact identity and in vivo function, are still unknown.

One disadvantage of the conventional in vitro method for isolating MSCs is the unavoidable contamination by hematopoietic cells and the cellular heterogeneity of the cultures, including various fibroblastic cells. In fact, depending on the study, cultured MSCs express a different subset of various cell lineage–specific antigens, adhesion molecules, integrins, and growth factor receptors (Jiang et al., 2002; da Silva Meirelles et al., 2006). Another problem with the current technique is that the cultured cells may acquire different characteristics from their in vivo state, which could include changes in the cell surface markers they express. One example of adherent culture-induced change is seen when MSCs, which are readily expanded in culture without loss of multipotency, show poor tissue tropism when transplanted, including a failure to migrate to the BM (Rombouts and Ploemacher, 2003; Wang et al., 2005; Muguruma et al., 2006; Sackstein et al., 2008), which limits their therapeutic usefulness. In contrast, some studies (including the current one) show that primary BM-derived MSCs (assayed as CFU-Fs) show a low but efficient seeding of the BM upon injection into lethally irradiated hosts (Rombouts and Ploemacher, 2003; Koide et al., 2007). Because these changes affect fundamental properties of the cells, it is difficult to know whether they have retained or lost their original characteristics, including their apparent multipotency, in vitro.

Most studies on MSCs have been done using human cells, not murine cells. Murine MSCs (mMSCs) are far more difficult to isolate from the BM and to expand in culture than human MSCs (Phinney et al., 1999; Sun et al., 2003; Peister et al., 2004). Thus, there is much less information on mMSCs than on human MSCs. This reliance on human material means that MSCs cannot be studied in genetic mouse models, which greatly hinders the study of their basic biology, engraftment, and therapeutic potential. In fact, without some means for the prospective isolation and purification of MSCs, it becomes extremely difficult to ascribe any attribute to them with certainty. Hence, there is a clear need for specific markers and methods of detection, enumeration, and isolation of MSCs from the BM and other tissues where they reside.

In a previous study, we identified several mesenchymal lineage specific markers in murine BM cells (Koide et al., 2007), and after initial screening, we determined two possible MSC markers (Morikawa et al., 2009), platelet-derived growth factor receptor α (PDGFRα; an early mesodermal marker; Takakura et al., 1997) and stem cell antigen-1 (Sca-1; a known stem cell marker; Ortega et al., 1986).

Here, we report a method for identifying and isolating MSCs from the adult murine BM, using flow cytometry in combination with in vitro function assays. We also report our findings on their physiological role, obtained through existing in vivo precursor cell transplantation assays. We describe cell type–specific markers for MSCs, which are useful for their prospective isolation as a highly enriched population that gives rise to mesenchymal cells at the clonal level with high frequency, and demonstrate that these cells are capable of in vivo grafting when transplanted systematically.

RESULTS

The PoS population is significantly enriched for CFU-Fs with differentiation potential

Freshly prepared BM cells were stained with antibodies to PDGFRα, Sca-1, CD45, and TER119, and analyzed by flow cytometry. First, the hematopoietic (CD45+/TER119+) cells were removed from the population by gating on the marker signals (Fig. 1, A and C). In the CD45−TER119− gate, four distinct subpopulations (PDGFRα+/Sca-1+, PDGFRα−/Sca-1−, PDGFRα+/Sca-1−, PDGFRα−/Sca-1−) were observed (Fig. 1 B). Interestingly, the frequency of cells expressing PDGFRα or Sca-1 significantly increased when the BM was extracted using collagenase treatment (Fig. 1, B and D; see Materials and methods).

To test whether PDGFRα or Sca-1 could be used for the prospective isolation of mMSCs, we isolated cells in each subpopulation from freshly isolated BM mononuclear
cells (BMMNCs) and performed several in vitro assays to determine their characteristics. A traditional CFU-F assay showed that the number of colonies per 1,000 cells was highest in the PDGFα^Sca-1^-CD45^TER.119^- (PaS) subpopulation; however, the cells in the other subpopulations still produced a significant number of colonies (Fig. 1 E). Conventional MSC culture conditions (Phinney et al., 1999; Pittenger et al., 1999) yielding fibroblastic/spindle-shaped cells indicative of MSCs were only derived in the PaS cultures on day 14 (Fig. 1 F, top right). The other subpopulations showed different morphologies, such as the cobblestone appearance typical of endothelial cells, observed in the PDGFα^Sca-1^- group (Fig. 1 F). In addition, an analysis of growth kinetics revealed that only the PaS cells proliferated without senescence, yielding more than 10^7 cells from the original 5,000 cells seeded, with a doubling time of 50.6 h (Fig. 1 G).

We also observed a negative linear relationship between seeding density and colony formation efficiency (Fig. 1 H; Stingl et al., 2006). In unfractionated BMMNCs, isolated without collagenase treatment, the frequency of CFU-Fs was 1/2.6 × 10^6 cells, as described previously (Phinney et al., 1999). It was 100 times greater when collagenase treatment was used (1/3.6 × 10^6). The frequency of CFU-Fs obtained from PaS cells was 1 per 22.5 cells, which was consistent with the bulk CFU-F assays (Fig. 1 E). Collectively, the PaS cells showed a 120,000-fold higher CFU-F frequency than the unfractionated BMMNCs.

The PaS cells' potential for in vitro mesenchymal lineage differentiation was also investigated (Fig. 1 I). Freshly prepared BM cells were separated into the four CD45^-TER.119^- subpopulations described above, cultured with maintenance media for one or two passages, and then grown in differentiation-induction media for an additional 14–21 d. Only the PaS cells differentiated robustly into adipocytes, chondrocytes, and osteocytes. Although other fractions formed a pelletable micro-mass when grown under chondrogenic conditions, the extracellular matrix was either scarce or absent, as tested by toluidine blue staining. Adipocytes were generated almost solely by the PaS population, although a very few were occasionally seen in the PDGFα^Sca-1^- population. PaS cells were also detected in the BM of other mouse strains, and showed both high colony-forming frequency and trilineage differentiation potential at levels comparable to the C57BL/6 PaS cells (Fig. S1).

As might be expected for MSCs, the PaS cells did not have any hematopoietic capacity in vitro. They did not contain any CFUs under hematopoietic culture conditions, whereas sorted HSCs (CD34^-KSL cells) formed over 80 colonies per 100 cells under the same conditions (Fig. 1 J and K). Notably, flow cytometric analysis showed that the PaS BM fraction did not contain any side population (SP) cells, a population enriched for stem cells, including HSCs, derived from a variety of tissues (Fig. 1 L; Goodell et al., 1996; Ono et al., 2007; Oyama et al., 2007).

A single, self-renewing PaS cell can give rise to mesenchymal and endothelial lineages

To test the hypothesis that PaS cells contained MSCs that could differentiate into all three lineages, and to rule out the possibility that the PaS population contained several different kinds of committed progenitors, we performed a differentiation assay with expanded cell colonies derived from a single PaS cell. For this experiment, sorted PaS cells were plated at a density of ~1-2 × 10^3 cells on a 100-mm dish. 60 individual colonies of 50–100 cells were isolated ~14 d after plating (Fig. 2 A). After several passages, 6 of the 60 independent clones were selected for further study and subjected to in vitro differentiation assays.

All six clones showed osteogenic and chondrogenic differentiation, assessed by alkaline phosphatase/toluidine blue staining and the expression of bone and cartilage-related genes, including *osteopontin*, *ostecalcin*, *PTHR*, *collagen II*, *collagen X*, and *aggrecan*. Four (clones 7, 11, 17, and 19) also underwent adipogenic differentiation, demonstrated by oil red O staining and the expression of fat-related genes, including *adipin*, *PPARγ*, and *mLP* (Fig. 2 B and C). Interestingly, these four clones also underwent angiogenic differentiation, as shown by staining for endothelium-associated proteins (PECAM-1 and VE-cadherin). These results suggest that MSCs are precursors for both mesenchymal and endothelial lineages.

Flow cytometric analysis of clones from single cells revealed uniform expression of conventional mesenchymal markers CD29, CD49e, CD44, and Sca-1, but only heterogeneous expression of CD105 and CD90, which are known as marker for cultured human MSCs. Clones with multilineage differentiation potential (#7, 11, 17, and 19) were CD105^-CD90^, unlike those with limited differentiation potential (#26, 42). This observation suggests that CD105 and CD90 may be useful indicators for multipotency of cultured mMSCs (Fig. S2).

PaS cells reside in the perivascular space in vivo

The data presented so far convinced us that the PaS population represented primary mMSCs. Therefore, we further investigated the in vivo localization and cell-surface phenotype of naive PaS cells by whole-mount immunohistochemistry (whole-mount IHC) and flow cytometry. As far as we observed in >100 microscopic fields of three individual wild-type C57BL/6, all PaS cells were located in the arterial perivascular space near the inner surface of the cortical bone (Fig. 3 A), adjacent to vascular smooth muscle cells (vSMCs) in BM (Fig. 3 B). PDGFα was expressed in a broader cell population that included cells with reticular morphology, and relatively weak Sca-1 expression was detected in the endothelial cells (Fig. 3 B).

Because reticular cells located in the perivascular space act as hematopoietic niche cells (Sugiyama et al., 2006), we used quantitative RT-PCR (Fig. 3 C) and IHC (Fig. 3 D) to examine the expression of two major paracrine factors that maintain hematopoiesis: angiopoietin-1 (*Ang-1*; Arai et al., 2004) and CXCL12 (Sugiyama et al., 2006). We found abundant
expression of Ang-1 in the PaS cells and of CXCL12 in the PDGFRα Sca-1- cells, suggesting that the MSCs constitute a hematopoietic niche in the arterial perivascular area near the endosteum (Moore and Lemischka, 2006).

Flow cytometric analysis of fresh BMMNCs (Fig. 3 E) revealed that PaS cells uniformly expressed known markers for cultured human MSCs (CD29, CD49e, CD105, CD133, and PDGFRβ). Endothelial cell markers (Flk-1, VEGFR3, and CD146, except for CD34) were also uniformly expressed, although the fluorescence intensities were lower than that of the markers for cultured human MSCs. Markers for HSCs (c-kit and CD150) were totally negative. The cells showed expression of Ang-1 in the PaS cells and of CXCL12 in the PDGFRα Sca-1- cells, suggesting that the MSCs constitute a hematopoietic niche in the arterial perivascular area near the endosteum (Moore and Lemischka, 2006).

Flow cytometric analysis of fresh BMMNCs (Fig. 3 E) revealed that PaS cells uniformly expressed known markers for cultured human MSCs (CD29, CD49e, CD105, CD133, and PDGFRβ). Endothelial cell markers (Flk-1, VEGFR3, and CD146, except for CD34) were also uniformly expressed, although the fluorescence intensities were lower than that of the markers for cultured human MSCs. Markers for HSCs (c-kit and CD150) were totally negative. The cells showed expression of Ang-1 in the PaS cells and of CXCL12 in the PDGFRα Sca-1- cells, suggesting that the MSCs constitute a hematopoietic niche in the arterial perivascular area near the endosteum (Moore and Lemischka, 2006).

Flow cytometric analysis of fresh BMMNCs (Fig. 3 E) revealed that PaS cells uniformly expressed known markers for cultured human MSCs (CD29, CD49e, CD105, CD133, and PDGFRβ). Endothelial cell markers (Flk-1, VEGFR3, and CD146, except for CD34) were also uniformly expressed, although the fluorescence intensities were lower than that of the markers for cultured human MSCs. Markers for HSCs (c-kit and CD150) were totally negative. The cells showed expression of Ang-1 in the PaS cells and of CXCL12 in the PDGFRα Sca-1- cells, suggesting that the MSCs constitute a hematopoietic niche in the arterial perivascular area near the endosteum (Moore and Lemischka, 2006).

Figure 2. Identification of MSC potential by clonal assay. (A) Phase-contrast micrographs of a representative colony from a single PaS cell. Bar, 200 µm. (B) Comparison of the differentiation potential of clonally derived cells. Adipogenic (day 14), chondrogenic (day 21), osteogenic (day 14), and endothelial (anti-PECAM-1+ and VE-cadherin+, day 21). Bars, 100 µm. (C) RT-PCR analysis of transcription factors and lineage-specific genes. Expression of adipocyte- (Adipsin, PPARγ, and mLP), chondrocyte- (CollagenII, CollagenX, and Aggrecan), and osteocyte-specific (Osteopontin, Osteocalcin, and PTHr) markers, 3 wk after differentiation induction. Data are representative of five independent experiments.
Figure 3. In vivo localization and phenotype of PdxS cells. Whole-mount IHC was performed in bone marrow from wild-type C57BL/6 animals. (A) Representative results for quadruple IHC of PDGFRα (green), Sca-1 (red), αSMA (white), and DAPI (blue) in untreated bone marrow. (B) High magnification image of the boxed area in A. PdxS cells (arrows), vascular smooth muscle cells (arrowheads). Data are representative of three independent recipients. (C) Quantitative RT-PCR analysis of Ang-1 and CXCL12. The expression levels detected in PDGFRα⁻ Sca-1⁻ cells were defined as 1 for each experiment. Mean ± SEM; n = 6 per group. (D) Triple IHC of Sca-1 (red), DAPI (blue), and Ang-1 (green, top left) or CXCL12 (green, bottom left). Data are representative of three independent recipients. (E) Representative results of flow cytometric analysis for cell-surface markers by using freshly isolated BMMNCs from wild-type C57BL/6 animals of three independent experiments. Blue line, isotype control; red line, specific antibodies. Bars: (A, B, and D) 50 µm.
heterogeneous expression of the endothelial cell marker CD34, cultured MSC marker CD90, and endothelial cell/HSC marker Tie-2.

**PαS cells repopulate hematopoietic niche components and adipose tissue in vivo**

Although the transplantation of mesenchymal stem cells has not been believed to be feasible (Wang et al., 2005; Sackstein et al., 2008), we and several other groups have reported that freshly isolated BM cells can replace a part of mesenchymal or stromal cells (Hou et al., 1999; Pereira et al., 1998; Rombouts and Ploemacher, 2003; Koide et al., 2007). To examine whether naive MSCs can reconstitute the BM in vivo, freshly isolated 10^6 PαS cells from CAG-EGFP transgenic mice (EGFP^+ CD45.1^+) were intravenously injected into lethally irradiated recipient mice (EGFP^− CD45.1^−) along with 100 CD34^− KSL cells (HSCs sorted from EGFP^− CD45.1^+ mice; Fig. 4). The cells derived from PαS or HSCs were traceable by their expression of EGFP or CD45.1, respectively.

At 16 wk, the peripheral blood of 10 out of 10 recipients had been reconstituted by HSC-derived CD45.1-positive cells averaging 81.1 ± 4.9% of the total cells counted (unpublished data). The recipient animals were subsequently sacrificed and BM sections were subjected to whole-mount IHC. We found a significant number of PαS-derived GFP^+ cells in the BM and surrounding bone tissue in all recipients. The majority of the cells were located in the perivascular region or apposing the inner-surface of cortical bone (Fig. 4 A). Double IHC for GFP and marker molecules revealed that the transplanted PαS cells differentiated into reticular cells in association with vSMCs (Fig. 4 B, a−c), consistent with the normal physiological localization of PαS cells (Fig. 3 A and B). The CXCL12 (Fig. 4 B, d−f) and Ang-1 (Fig. 4 B, g−i) expression in these cells suggested they could reconstitute the vascular niche for hematopoiesis. GFP-positive PαS cells had also differentiated into osteocalcin-expressing osteoblasts lining the inner surface of the cortical bone (Fig. 4 B, j−l). In addition, in the adipose tissue of recipient mice we found some GFP-positive cells that were also positive for perilipin (Fig. 4 B, m−o), an adipocyte marker that is specifically expressed at the periphery of lipid droplets (Cho et al., 2007). Combined with the localization of naive PαS cells in BM shown in Fig. 3 (A−D), the data suggested that within 16 wk of systemic transplantation, primary PαS cells (MSCs), which are normally located in the arterial perivascular space in association with vSMCs, can give rise to osteoblasts and perivascular cells that function as hematopoietic niche cells (Fig. S3) or produce adipocytes when the cells migrate to adipose tissue.

However, systemically transplanted GFP^+ MSCs derived from single PαS cells in culture were not detectable 8 wk later. To investigate this further, 10^6 1-mo-culture-expanded PαS cells that had been engineered to express firefly luciferase fused to Venus (see Materials and methods) were transplanted into lethally irradiated recipient mice. The animals were subjected to bioluminescence imaging (BLI) analysis (Okada et al., 2005)
on days 0, 1, 3, 7, and 14 after transplantation. Strong bioluminescent signals in the bilateral lung and neck were observed on days 0, 1, and 3, but the signals attenuated below the level of detectability by day 7 (Fig. S4). The data strongly support a previous observation that MSCs rapidly lose their ability to home to an appropriate site when cultured (Rombouts and Ploemacher, 2003; Wang et al., 2005).

We further investigated whether transplanted PαS cells maintained their stem cell properties by observing whether secondary CFU-Fs could be clonally expanded, which would indicate their competence for self-renewal. At 16 wk after transplantation, the bone and BM of five recipient mice were individually collagenase digested into single-cell suspensions. Flow cytometric analysis showed that donor-derived GFP+ nonhematopoietic (CD45-TER119-) cells (Fig. 5 A, left) were <10% (mean percentage 7.35%), although the percentage varied in all cases. Notably, GFP+ cells belonging to populations other than PαS were found (Fig. 5 A, right). To test
if the recovered PtS cells retained their stem cell properties, we sorted single PtS cells into individual wells of 96-well plates, and analyzed the resulting colonies. GFP+ fibroblastic colonies generated from 2 of 96 cells (Fig. 5 B), and the 2 clones retained the ability to undergo sustained growth, as well as the multilineage differentiation potential in vitro (Fig. 5 C).

PtS cells are resistant to whole-body irradiation

Although our data showed that the prospectively isolated PtS cells (primary MSCs) migrated to appropriate sites and differentiated into the expected cell types after systemic infusion, the mean chimerism resulting from the transplantation of 10^4 PtS-derived cells was ~7%. In contrast, 100 purified HSCs were sufficient to reconstitute >80% of the hematopoietic cells (Fig. 5 A). Given that 10^3 PtS cells contained ~500 CFU-Fs, based on our 1/20 frequency of CFU-Fs in PtS cells (Fig. 1 H), the PtS engraftment was lower than expected. The observed difference might have been caused by the irradiation protocol. That is, if the recipient’s MSCs had not been eliminated in sufficient numbers to leave their niche available to the donor MSCs, competition for the niche might have reduced the number of successfully engrafted cells (Rombouts and Ploemacher, 2003; Koide et al., 2007). To evaluate this hypothesis, we compared the susceptibility of HSCs (KSL) and MSCs (PtS) to irradiation.

Three mice in each group were subjected to whole-body irradiation at a dose of 10.5 Gy; a significant number of PtS cells remained among the BMNNCs after 6 d, but the HSCs (KSL cells) were almost undetectable by flow cytometry (Fig. 6, B and D). Interestingly, the sorted PtS cells from the irradiated animals mostly failed to form colonies, and the CFU-F frequency was reduced to 1.66 ± 0.57% (33 ± 5.0% in unirradiated; Fig. 6 C). Because irradiation normally induces cell death in actively cycling cells, we reasoned that the MSC/PtS cells were quiescent. Flow cytometric analysis for cell-cycle markers showed that 71% of freshly isolated PtS cells were in the G0 phase (Fig. 6 E), which could have protected them from lethal irradiation. These findings suggest that a significant proportion of the PtS cells are physiologically quiescent and therefore resistant to radiation damage and myelotoxicity in vivo.

DISCUSSION

Using cell-surface markers and flow cytometry, we succeeded in prospectively isolating MSCs as PDGF-Rα^+ Sca-1^-CD45^- TER119^- (PtS) cells from adult murine BM. We showed that PtS cells have primitive characteristics consistent with conventional MSC populations isolated by adhesion culture. Because PtS cells were detected in various mouse strains (Fig. S1) with equal CFU-F frequency and differentiation potency, our protocol has immense potential for isolating enriched, primary MSCs for detailed analyses especially in various genetically modified animals. Unlike with conventional protocols, our protocol permits such studies to be done with minimal contamination by unnecessary cells or the potential alteration of cell characteristics by ex vivo expansion.

The identification of a marker combination that permits the isolation of primary MSCs enabled us to examine their physiological localization and role in the BM. We found that primary MSCs, with abundant Ang-1 expression, were predominantly in the arterial perivascular space near the inner surface of the bone, adjacent to VSMCs. Our data also demonstrated the in vivo fate of primary MSCs in a systemic transplantation assay. The transplanted primary MSCs (PtS cells) mainly differentiated into osteoblasts and Ang-1– and/or CXCL12–expressing perivascular cells, consistent with a recent study (Sacchetti et al., 2007). Collectively, our data conclusively demonstrate that primary MSCs and their descendants mainly function in the adult BM as a hematopoietic niche in the arterial perivascular area in BM (Doherty et al., 1998; Shi and Gronthos, 2003).

One of the most important observations of this study is that intravenously transplanted PtS cells were integrated not only into the BM but also into adipose tissue. Previous studies have largely indicated that MSCs are not transplantable. The systemic delivery of in vitro–isolated MSCs to recipient animals, although feasible, has been limited by the entrapment of donor cells in tissues, primarily the lungs, and the few successful transplantations were mostly performed by direct local or intraosseous implantation (Miyahara et al., 2006; Muguruma et al., 2006).

As has been reported (Rombouts and Ploemacher, 2003), we found that cultured MSCs lost their homing ability. In addition, after ex vivo expansion, even the PtS cells were largely trapped in the lung (Fig. S4) and did not contribute to any BM compartment. Cell migration and tissue integration involve a cascade of events initiated by shear-resistant adhesive interactions between flowing cells and the vascular endothelium at the target tissue. This process is mediated by “homing receptors” expressed on circulating cells that engage relevant endothelial coreceptors, resulting in cell-tethering and rolling contacts on the endothelial surface; this is typically followed by chemokine–triggered activation of integrin adhesiveness, firm adhesion, and extravasation (Sackstein, 2005). The key molecule that mediates the homing capacity of primary MSCs is unknown, and its identification should be addressed in a future study. In addition, it is also possible that BM-engrafted cells and CFU-Fs were derived from a distinct cell population because PtS cells still contain a heterogeneous population of cells. Thus, further purification and clonal transplantation studies would be necessary to prove our hypothesis.

Although cultured MSCs are multipotent in vitro, the cells often commit to the osteocyte lineage after local implantation (Sacchetti et al., 2007). We found that transplanted PtS cells that migrated to the BM mainly produced niche cells, as described above, but the cells that localized to adipose tissue differentiated into mature adipocytes. These results strongly suggested that primary MSCs can home to their appropriate niche and differentiate in response to cues from the local microenvironment. However, the discrepancy in differentiation potential between the in vitro and in vivo data remains to be addressed. In the in vitro differentiation assay,
Figure 6. In vivo effects of lethal irradiation on the quiescence of PaS cells. HSCs (CD34+ KSL) from B6-Ly5.1 (CD45.1) mice and PaS cells (MSCs) from CAG-EGFP transgenic mice were transplanted together into lethally irradiated B6-Ly5.2 mice to examine the competitive repopulation of the appropriate niches. The graph shows the percentage of CD45.1 and GFP donor-derived cells detected in the BM of recipient mice 16 wk after transplantation (CD45.1, 81.1 ± 4.95%; GFP+, 7.4 ± 0.40%; n = 3 per group in three independent experiments). (B) The numbers of HSCs (KSL, c-Kit+Sca-1−Lin−) and MSCs (PaS, PDGFRα+Sca-1+) in the BM were calculated by ([Total number of BMMNCs] × [% of the cells] /100). Black bar, untreated control mice; gray bar, irradiated mice, 10 d after lethal irradiation. Results are means ± SEM (n = 3 per group). (C) The number of CFU-Fs formed from PaS cells isolated from either of unirradiated control (black) or lethally irradiated (Gray) wild-type C57BL/6. Means ± SEM (n = 3 per group). (D) Representative flow cytometric analysis of HSCs (KSL, top) or MSCs (PaS, bottom) in BMMNCs of lethally irradiated or unirradiated control mice. (E) Flow cytometry analysis of PY/Hoechst-stained PaS cells of unirradiated (left) and lethally irradiated (right) mice. Data are representative of three independent experiments.
single Pa\$S-derived MSCs differentiated not only into chondrocytes and osteocytes, but also into endothelial cells and adipocytes. However, the primary Pa\$S cells did not integrate into vSMCs in vivo. In addition, at least within 3 mo after transplantation, there were no detectable Pa\$S-derived adipocytes in the BM. One explanation may be that naive MSCs are extremely sensitive to tissue level elasticity in the microenvironment and commit to specific lineages accordingly (Engler et al., 2006).

These findings have important clinical implications. Primary MSCs transplanted by systemic infusion may be useful for cell therapy of various systemic skeletal diseases, such as dyschondroplasia, osteochondrodysplasia, osteoporosis, and osteogenesis imperfecta. In contrast, local implantation is invasive and can result in significant morbidity, potentially disrupt the highly complex and delicate structure of the local regulatory microenvironment, and cause additional injury. Thus, stem cell–based therapy for systemic disorders mandates vascular delivery. However, this approach is limited by the difficulty of ensuring that sufficient numbers of reconstituting cells reach the damaged areas in cases of ineffective stem cell engraftment (Laver et al., 1987; Simmons et al., 1987; Agematsu and Nakahori, 1991; Awaya et al., 2002; Stute et al., 2002; Barbash et al., 2003; Meyerrose et al., 2007). Here, we demonstrated the detection of significant number of primary Pa\$S-derived cells in the BM of transplant-recipient animals; however, the low engraftment activity of MSCs remains an unsolved problem. A key feature of stem cells is that they are in a quiescent state in vivo. Our results clearly revealed that >70% of Pa\$S were in the G_0 phase, and the frequency of quiescent Pa\$S in the BM did not change after lethal irradiation. These data demonstrate that although the radiation reduced the host CFU–F colony-forming ability in vitro, it did not physically kill the cells; instead, they remained alive, but mostly nonfunctional, in their niche. Finding nonlethal ways to remove host MSCs, assuming that the cell cycle progression of transplanted MSCs can be induced, to expand the progenitor population and compensate for cell loss, will be our next challenge. If we succeed, freshly isolated MSCs could have great potential for correcting bone and BM-related systemic disorders.

Overall, the approach detailed here provides a means for researchers to study the therapeutic potential of cells from BM as a cell source for bone components and to elucidate how individual factors function in the control and maintenance of bone and BM formation in vivo and in a variety of health and disease states. Advances in this field hold promise for the development of rationale–based stem cell therapies for tissue regeneration and of gene therapy for inherited disorders.

MATERIALS AND METHODS

Mice

Adult wild-type C57BL/6 mice and B6.SJL-Ptprca Pep3b/Boyj (C57BL/6-Ly5.1,Ly5.2) mice 8–12 wk of age were purchased from CLEA Japan, Inc. (Tokyo, Japan). Transgenic mice that ubiquitously express EGFP under the control of the CAG promoter (Kawamoto et al., 2000) were bred in our animal facility. The mice were kept under specific pathogen–free conditions in our animal facility at Keio University School of Medicine. All experimental procedures and protocols were approved by the ethics committee of Keio University and were in accordance with the Guide for the Care and Use of Laboratory Animals.

Preparation of BM cell suspension

Femurs and tibias were dissected and crushed with a pestle. The crushed bones were gently washed once in HBSS+ (Hanks-balanced salt solution supplemented with 2% FBS, 10 mM Hepes, and 1% penicillin/streptomycin), and the cell suspension filtered through a cell strainer (Falcon 2530) was discarded. The bone fragments were collected and incubated for 1 h at 37°C in 20 ml of DMEM (Invitrogen) containing 0.2% collagenase (Wako Chemicals USA, Inc.), 10 mM Hepes and 1% P/S. The suspension was filtered with a cell strainer (Falcon 2530) to remove debris and bone fragments, and collected by centrifugation at 280 g for 7 min at 4°C. The pellet was immersed in 1 ml water (Sigma–Aldrich) for 5–10 s to burst the red blood cells, after which 1 ml of 2× PBS (dilution from Sigma–Aldrich) containing 4% FBS was added, and the suspension was filtered through a cell strainer.

Antibody staining

The cells were suspended in ice-cold HBSS+ at 1–5 × 10^6 cells/ml, and then stained for 30 min on ice with the following mAbs: biotinylated or APC-conjugated PDGFR\(\alpha\) (APAS), FITC-conjugated Sca-1 (Ly6A/E), PE-conjugated CD45 (30-F11), and TER119 (TER-119). Biotinylated antibodies were visualized with APC-conjugated streptavidin (Invitrogen). All mAbs were purchased from eBioscience. Flow cytometry analysis and sorting were performed on a triple-laser MoFlo (Dako) or FACS\(\text{C}^\text{alibur}\) (BD) flow cytometer. PI fluorescence was measured, and a live cell gate was defined that excluded the cells positive for PI. Additional gates were defined as positive for PDGFR\(\alpha\) and Sca-1 and negative for CD45 and TER119, according to the isotype control fluorescence intensity.

Cell culture

A variety of culture methods were required for this study, including adherent culture, CFU–F assay, cultures for MSC differentiation into mature cells, and CFU–C assay.

Adherent culture. Traditional MSC adherent culture was performed as described previously (Pittenger et al., 1999). Sorted cells were cultured in maintenance medium (i.e., MEM\(\alpha\) + GlutaMAX-I [Invitrogen] supplemented with 10% FBS and antibiotics), incubated at 37°C with 5% CO_2, and maintained with exchanges into fresh medium every 3–4 d for 2–3 wk.

CFU–F assay. Approximately 1 × 10^5 or 2 × 10^5 sorted cells were seeded on a 100-mm dish in maintenance medium. Adherent cell clusters containing >50 cells were counted as a colony.

Differentiation cultures. To induce adipocyte differentiation, subconfluent cells were cultured with three cycles of Adipogenic Induction Medium/Adipogenic Maintenance Medium, with supplements from the Adipogenic Induction/Adipogenic Maintenance SingleQuot kit (Lonza). Each cycle consisted of feeding the subconfluent cells with the induction medium for 3 d, followed by 3 d of culture in the maintenance medium. After 14 d, the cells were fixed with 4% paraformaldehyde for 15 min, and stained with oil red O (MutoPure Chemicals).

For chondrogenic differentiation, cultured cells were harvested by trypsinization. The 2 × 10^5–2.5 × 10^6 cells were transferred into a 15-ml conical tube and washed with MEM\(\alpha\) + GlutaMAX (Invitrogen). The tube was spun at 150 g for 5 min at room temperature, and the supernatant was aspirated. The cells were resuspended in 1 ml Differentiation Basal Medium Chondrogenic, with supplements from the Chondrogenic SingleQuot kit (Lonza), spun at 150 × g for 5 min, and the medium was aspirated. The cells were resuspended in 1 ml of Differentiation Basal Medium Chondrogenic, supplemented with Chondrogenic SingleQuots kit, TGF–b3 (10 ng/ml; Lonza) and BMP–6 (500 ng/ml; R&D Systems), and spun at 150 g for 5 min at room temperature. The pellet was maintained with Differentiation Basal
Medium changes every 3–4 d for 3 wk. After 3 wk, cell clumps were harvested, washed in 4% paraformaldehyde, and stained with toluidine blue.

To induce osteocyte differentiation, subconfluent cells were cultured with Differentiation Basal Medium Osteogenic, supplemented with Osteogenic SingleQuotes (Lonza) for 14 d. The cells were then fixed with 4% paraformaldehyde for 15 min and stained with alkaline phosphatase (Histofine; Nichirei).

For vasculogenesis, sorted cells were seeded on poly-L-ornithine/ fibronectin (Sigma-Aldrich)-coated 8-well chamber slides (Iwaki) with Endothelial Cell Basal Medium-2 (EBM-2), supplemented with EGM-2 MV SingleQuotes (Lonza), and incubated at 37°C with 5% CO₂. The cultures were maintained with medium changes every 4–7 d for 3 wk.

**CFU-C assay.** Cell suspensions were mixed with MethoCult (StemCell Technologies). Cells were plated in 35-mm dishes and cultured at 37°C with 5% CO₂. Colonies were scored on day 14.

### Negative linear relationship assays

In this assay, the systematic dilution of cells reduces the plating cell density and increases the incidence of wells with no colonies. The sorted cells were seeded into 96- or 24-well plates or 100-mm dishes containing 14 cell-dose groups: 25; 50; 100; 200; 400; 500; 800; 5,000; 10,000; 50,000; 80,000; 1,000,000; 2,500,000; or 5,000,000 sorted cells per well. After 14 d, each well was fixed in methanol, stained with Giemsa, and the wells with no colonies were included in the count for each population. The concentration of cells plated in which 37% of the wells are negative for colony growth is the cell concentration that contains one CFU-F (Bacon and Sytkowski, 1987).

### RT-PCR and quantitative RT-PCR (QRT-PCR) assay

RT-PCR was performed as described previously (Koide et al., 2007). The QRT-PCR assay was performed on an ABI 7500 Fast Real-Time PCR System using TaqMan Fast Universal PCR master mixture (Applied Biosystems) and TaqMan Gene Expression Assay mix for Ang-1 (Mm00458503_m1) or CXCL-12 (Mm00445552_m1). The β-actin (actb) assay mix (Mm00607939_s1) served as an endogenous control. Data were analyzed by 7500 Fast System SDS Software 1.3.1. All experiments were done in quadruplicate.

### In vivo transplantation

CD34+KSL cells (HSCs) from Ly5.1 congenic mice and PöS cells from CAG-EGFP transgenic mice were isolated as described above. Then, a mixture of 100 HSCs and 10⁶ PöS cells were transplanted intravenously into the retro-orbital plexus of anesthetized recipient mice that had been lethally irradiated (10.5 Gy) along with 2 × 10⁴ whole BM cells from recipient strain mice, as radioprotective cells.

### Immunostaining of BM and adipose tissue

For BM and adipose tissue sections, whole-mount staining was performed as previously described (Kubota et al., 2008). The following antibodies were used as a primary antibodies: anti-GFP (rabbit IgG; 1:500; MBL; and goat IgG; 1:200; Santa Cruz Biotechnology, Inc.), α-SMA (1A4; FITC or Cy3-conjugated; Sigma-Aldrich), Sca-1 (D7; BD), PDGFRα (Santa Cruz Biotechnology, Inc.), Ang-1 (Santa Cruz Biotechnology, Inc.), CXCL12 (Abcam), osteocalcin (Santa Cruz Biotechnology, Inc.), and perilipin (Research Diagnostics). The secondary antibodies used were Alexa Fluor 488 fluorescence-conjugated IgGs (Invitrogen) or Cy3/Cy5-conjugated IgGs (Jackson Immunoresearch Laboratories). For nuclear staining, specimens were treated with DAPI (Invitrogen).

### Infection of lentivirus expressing firefly luciferase fused to Venus and preparation of transduced PöS cells

By using the fluorescent and luminescent fusion protein, the success of lentivirus infection was confirmed with fluorescent signal from Venus. After the transplantation, the spot(s) of transplanted PöS cells were followed by bioluminescent signal from Luciferin in mice body. Because we used the modified bioluminescent protein which emitted bigger bioluminescent signals than general one, only 10⁶ cells could be detected easily. Sorted single PöS cell was cultured and proliferated, infected with lentivirus, continuously propagated, harvested, and then dissociated into single cells. The PI-negative/Venus-positive PöS cells were sorted by a flow cytometry and transplanted with HSCs (34-KSL).

### BLI

We used a Xenogen-IVIS 100-cooled CCD optical macroscopic imaging system (SC BioScience Corporation) for BLI. For in vivo imaging, recipient mice transplanted with lentivirally engineered PöS cells were anesthetized and given D-luciferin (150 mg/kg body weight) i.p. We found this time window to be optimal because the signal intensity peaked at 15 min after administration followed by a plateau of 20 min (unpublished data). All images were analyzed as described in Materials and methods. To quantify the measured light, regions of interest (ROI) were defined as lungs and all values were examined from an equal ROI.

### Statistical analysis

The Tukey-Kramer test was used to compare the frequencies of CFU-Fs among different groups. All reported *p*-values were obtained using the SPSS software package (SPSS 15.0J for Windows).

### Online supplemental material

Fig. S1 shows the quantification and differentiation of PöS cells isolated from different inbred mouse strains. Fig. S2 shows cell surface marker antigens of clonally cultured PöS cells. Fig. S3 is a schematic model of the physiological localization and behavior of MSCs in BM. Fig. S4 shows imaging of transplanted cultured MSCs in vivo. Table S1 lists primers used in this study. Table S2 lists monoclonal antibodies used in this study. Online supplemental material is available at http://www.jem.org/content/full/jem.20091046/DC1.

We thank Miyuki Ogawara and Takayuki Ohkawa for technical assistance and Lawrence Lein for proofreading this manuscript.

This work was supported by a grant from the Solution-Oriented Research for Science and Technology (SORST) program of the Japan Science and Technology Agency (JST) and from the Ministry of Education, Culture, Sports, Science and Technology (to H.O. and Y.M.), and also supported in part by a grant-in-aid from the Global Century COE program of the Ministry of Education, Science, and Culture of Japan to Keio University.

The authors have no conflicting financial interests.

Submitted: 12 May 2009
Accepted: 8 September 2017

### REFERENCES

Agematsu, K., and Y. Nakahori. 1991. Recipient origin of bone marrow-derived fibroblastic stromal cells during all periods following bone marrow transplantation in humans. Br. J. Haematol. 79:359–365. doi:10.1111/j.1365-2141.1991.tb08041.x

Arai, F., A. Hira, M. Ohnura, H. Sato, S. Matsuoka, K. Takubo, K. Ito, G.Y. Koh, and T. Suda. 2004. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 118:149–161. doi:10.1016/j.cell.2004.07.004

Awaya, N., K. Rupert, E. Bryant, and B. Torok-Storb. 2002. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp. Hematol. 30:937–942. doi:10.1016/S0091-7785(02)00821-4

Bacon, E.R., and A.J. Sytkowski. 1987. Identification and characterization of a differentiation-specific antigen on normal and malignant murine erythroid cells. Blood. 79:359–365. doi:10.1118/j.1365-2141.1991.tb08041.x

Barbash, L.M., P. Chourasqi, J. Baron, M.S. Feinberg, S. Etzion, A. Tesone, L. Miller, E. Guetta, D. Zipori, L.H. Kedes, et al. 2003. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 108:863–868. doi:10.1161/01.CIR.0000084828.50310.6A
Phinney, D.G., G. Kopen, R.L. Isaacson, and D.J. Prockop. 1999. Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. J. Cell. Biochem. 72:570–585. doi:10.1002/(SICI)1097-4644(19990315)72:4<570::AID-JCB12>3.0.CO;2-W

Pittenger, M.F., A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, and D.R. Marshall. 1999. Multilineage potential of adult human mesenchymal stem cells. Science. 284:143–147. doi:10.1126/science.284.5411.143

Prockop, D.J. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 276:71–74. doi:10.1126/science.276.5309.71

Rombouts, W.J., and R.E. Ploemacher. 2003. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia. 17:160–170. doi:10.1038/sj.leu.2402763

Sacchetti, B., A. Funari, S. Mitchenzi, S. Di Cesare, S. Piersanti, I. Saggio, E. Tagliafico, S. Ferrari, P.G. Robey, M. Riminucci, and P. Bianco. 2007. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 131:324–336. doi:10.1016/j.cell.2007.08.025

Sackstein, R. 2005. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr. Opin. Hematol. 12:444–450. doi:10.1097/01.moh.0000177827.78280.79

Sackstein, R., J.S. Merzaban, D.W. Cain, N.M. Daga, J.A. Spencer, C.P. Lin, and R. Wohlgemuth. 2008. Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat. Med. 14:181–187.

Shi, S., and S. Gronthos. 2003. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J. Bone Miner. Res. 18:696–704. doi:10.1359/jbmr.2003.18.4.696

Simmons, P.J., D. Przepiorka, E.D. Thomas, and B. Torok-Storb. 1987. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature. 328:429–432. doi:10.1038/328429a0

Smith, L.G., L.L. Weissman, and S. Heimfeld. 1991. Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc. Natl. Acad. Sci. USA. 88:2788–2792. doi:10.1073/pnas.88.7.2788

Spangrude, G.J., D.M. Brooks, and D.B. Tumas. 1995. Long-term repopulation of irradiated mice with limiting numbers of purified hematopoietic stem cells: in vivo expansion of stem cell phenotype but not function. Blood. 85:1006–1016.

Stingl, J., P. Eirew, I. Ricketson, M. Shackleton, F. Vaillant, D. Choi, H.I. Li, and C.J. Eaves. 2006. Purification and unique properties of mammary epithelial stem cells. Nature. 439:993–997.

Stute, N., B. Febse, J. Schröder, S. Arps, P. Adamietz, K.R. Held, and A.R. Zander. 2002. Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant. J. Hematother. Stem Cell Res. 11:977–984. doi:10.1089/152581602321080646

Sugiyama, T., H. Kohara, M. Noda, and T. Nagasawa. 2006. Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 25:977–988. doi:10.1016/j.immuni.2006.10.016

Sun, S., Z. Guo, X. Xiao, B. Liu, X. Liu, P.H. Tang, and N. Mao. 2003. Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem Cells. 21:527–535. doi:10.1634/stemcells.21-5-527

Takakura, N., H. Yoshida, Y. Ogura, H. Kataoka, S. Nishikawa, and S. Nishikawa. 1997. PDGFR alpha expression during mouse embryogenesis: immunolocalization analyzed by whole-mount immunohisto staining using the monoclonal anti-mouse PDGFR alpha antibody APAS. J. Histochem. Cytochem. 45:883–893.

Till, J., and E. McCulloch. 1961. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res. 14:213–222.

Wang, L., Y. Liu, Z. Kalajzic, X. Jiang, and D.W. Rowe. 2005. Heterogeneity of engrafted bone-lining cells after systemic and local transplantation. Blood. 106:3650–3657. doi:10.1182/blood-2005-02-0582